Clipperdistributing.info

MATERIAL SAFETY DATA SHEET

Product Name: Clindamycin Injection, USP
1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name
And Address
Hospira, formerly the Hospital Products Division of Abbott Laboratories, was created as an independent company in May 2004.
Emergency Telephone
Hospira, Inc.

Product Name

Synonyms
2. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient Name
Chemical Formula
Approximate Percent
Component
CAS Number
RTECS Number
by Weight

3. HAZARD INFORMATION

Emergency Overview
In clinical use, this material is used for the treatment of serious infection. The active ingredient may cause skin rash or allergic reaction upon ingestion. It has also been reported to cause irritation of the gastrointestinal tract in some patients.
Occupational Exposure
Information on the absorption of this compound via ingestion, Potential
inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact with solution.
Signs and Symptoms
No signs or symptoms from occupational exposure are known. In clinical use, clindamycins have been associated with rashes, colitis (diarrhea, abdominal cramps) and irritant responses.
Medical Conditions
Data suggest skin, eye or respiratory lesions, pre-existing gastrointestinal Aggravated by Exposure
distress or hypersensitivity to clindamycin or related antibiotics (e.g. lincomycin).
Product Name: Clindamycin Injection, USP

4. FIRST AID MEASURES
Eye Contact:
Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Skin Contact:
Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary.
Inhalation:
Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary.
Ingestion:
Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic / supportive care as necessary. 5. FIRE FIGHTING MEASURES
Flammability:

Fire & Explosion
Hazard:

Extinguishing Media:
Use extinguishing media appropriate for primary cause of fire.
Special Fire Fighting
No special provisions required beyond normal fire fighting equipment such Procedures
as flame and chemical resistant clothing and self contained breathing apparatus.
6. ACCIDENTAL RELEASE MEASURES
Spill Cleanup and Disposal
Absorb liquid with suitable material and clean affected area with soap and water. Dispose of materials according to the applicable federal, state, or local regulations.
7. HANDLING AND STORAGE
Handling
No special storage required for hazard control. For product protection store at controlled room temperature of 15-30°C (59-86°F).
Special Precautions

8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Exposure Guidelines
Exposure limits
Component OSHA-PEL
ACGIH-TLV
Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value. EEL: Employee Exposure Limit. STEL: 15-minute Short Term Exposure Limit. Product Name: Clindamycin Injection, USP

Respiratory Protection
Respiratory protection is not needed during normal product use.
Skin Protection
If solution contact with unprotected skin is likely, use of impervious gloves is a prudent practice.
Eye Protection
Eye protection is not required during expected product use conditions but may be warranted should a splash potential exist.
Engineering Controls
Engineering controls are not needed during normal product use conditions.
9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical
State
Odor
Boiling Point
Approximately that of water (100 °C, 212 °F). Freezing Point
Approximately that of water (0°C, 32 °F). Vapor Pressure
Approximately that of water (17.5 mm Hg at 20 °C). Vapor Density (Air=1)
Evaporation Rate Not
Bulk Density
Specific Gravity
Solubility

10. STABILITY AND REACTIVITY

Chemical Stability
Stable under standard use and storage conditions.
Incompatibilities None

Hazardous
Decomposition
Products

Hazardous
Polymerization

11. TOXICOLOGICAL INFORMATION:

Acute Toxicity - Oral

Ingredient(s) Percent
Type Value
LD50 is the dosage producing 50% mortality. Product contains approximately 15% Clindamycin.
Mutagenicity

Target Organ Effects
In clinical use target organ effects include gastrointestinal tract.
Product Name: Clindamycin Injection, USP

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity

13. DISPOSAL CONSIDERATIONS:

Waste Disposal
Disposal should be performed in accordance with the federal, state or local regulatory requirements.
Container Handling
Dispose of container and unused contents in accordance with federal, state, and Disposal

14. TRANSPORTATION INFORMATION

DOT
DOT - US Department of Transportation Regulations
15. REGULATORY INFORMATION

TSCA Status
CERCLA Status
SARA Status
RCRA Status
PROP 65 (Calif.) Not
TSCA Toxic Substance Control Act CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act SARA Superfund Amendments and Reauthorization Act RCRA US EPA, Resource Conservation and Recovery Act Prop 65, California Proposition 65
16. OTHER INFORMATION:

MSDS Coordinator
Disclaimer:
The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira
does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A
WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE
MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE.
Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results
obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No
warranty against infringement of any patent, copyright or trademark is made or implied.

Source: http://clipperdistributing.info/sites/default/files/Clindamycin%20Phosphate%20Injection.pdf